Insider buying last 90 days
$1.01Min 1 open-market purchase
| Filed | Insider | Type | Value |
|---|---|---|---|
| Sep 10 | Miles Patrick director, officer: CEO | Purchase | $1.01M |
From Form 4 filings, dated to when each was filed.
NASDAQ: ATEC
Alphatec (ATEC) Stock Analysis & Forecast
Oct 12 close
$11.25+0.58 (+5.4%)
Gekko Brief
AI summaryOct 12 closeThis week brings continued analyst attention to Alphatec, with Stifel Nicolaus maintaining a Buy rating and a $10.54 price target, part of a broader bullish tilt on select healthcare names including Zura Bio. Coverage also notes divergent trading signals around ATEC, pointing to choppy near-term conditions, alongside a Form 4 filing disclosing insider activity on 5 October.
ATEC closed at $11.25, up 5.4%, sitting between its 50-day average of $9.86 and 200-day average of $11.24, a trend picture that is mixed rather than clearly directional. The GekkoIndex reads 48.2, placing the stock in the Neutral zone, down 4 points over the past five readings. Shares trade 13.5% below Gekko Fair Value of $13.00, a gap that remains a point of reference against the current price.
Earnings are scheduled for 29 October 2026, after the close, 16 days out and within a typical 20-trading-day holding window; the prior report on 4 August showed an EPS miss against estimates and a 5.7% reaction, with an average absolute post-earnings move of 19.6% across recent quarters. Smart-money activity over the last 90 days includes one open-market insider purchase valued at $1,013,150. Seasonality over five years shows a 23.4% average 20-day return from this point in the calendar, with gains in 4 of those years, a pattern worth noting alongside the upcoming earnings date.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Alphatec price vs fair value
Close $11.25200-day averageGekko Fair Value $13.00
Alphatec quick facts
- Market cap
- $1.73B
- P/E ratio
- —
- Forward P/E
- 18.6
- EPS, TTM
- −$0.72
- Revenue, TTM
- $815.1M
- Profit margin
- -13.5%
- Dividend yield
- —
- Beta
- 0.78
- Volume
- 2.95M avg 2.14M
- 1-year return
- −18.2%
- Typical daily move
- ±4.1%
- Typical 20-day move
- ±10.1%
- 50-day average
- $9.86
- 200-day average
- $11.24
- Next earnings
- Oct 29 after close
- Shares outstanding
- 154.5M
Alphatec swing-trade checklist
Alphatec scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $11.25 sits between the 50-day ($9.86) and 200-day ($11.24) averages, or the averages disagree.
See the chart - GekkoIndexmixed
48.2, Neutral
Reading 48.2 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
13.5% below
Price is 13.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: 1 open-market insider purchase.
See smart money - Earnings riskheadwind
Reports in 17 days
Reports on Oct 29, 2026, 17 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+23.4% on average
From this point in the calendar, the next 20 trading days averaged +23.4% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Alphatec stock chart and price history
Alphatec closed at $11.25 on Oct 12, 2026, −18.2% over the past year, inside a 52-week range of $6.82 to $23.29.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +6.3%
- 3 months
- +25.4%
- 6 months
- 0.0%
- 1 year
- −18.2%
The full ATEC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ATEC in Gekko
Follow Alphatec through every session
Put ATEC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ATEC in GekkoFree for 7 days. No credit card required.
About Alphatec
Alphatec builds medical devices aimed at treating problems in the spine through surgery. Among its offerings is the Alpha InformatiX platform, which includes the SafeOp Neural InformatiX System, built to lower the chance of nerve damage while a procedure is underway. The company also makes tools for positioning and surgical access, such as the Sigma systems and the Squadron lateral retractor, along with an array of fixation hardware like Invictus, SingleStep, and the Arsenal platform, meant to support cases ranging from mild degeneration to more severe spinal deformity.
Beyond fixation devices, Alphatec supplies anterior and cervical plating products, a set of interbody implants, and biologic materials used to encourage bone healing, in addition to imaging equipment from its EOS line. To get these products into operating rooms, the company relies on a mix of independent distributors and salespeople employed directly by Alphatec, covering customers spread across the country.
Alphatec traces its founding back to 1990 and keeps its main offices in Carlsbad, California. Investors can find its stock listed on the NASDAQ under the ticker ATEC.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- atecspine.com
Alphatec GekkoIndex: the smart money zone
Alphatec’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 48.2, in the Neutral zone, down 4 points over five sessions.
48.2Neutral
Down 4 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 48 | −0.2% | +2.4% |
| Accumulation | 282 | +0.5% | +3.4% |
| Neutral (current zone) | 281 | −0.1% | −1.6% |
| Distribution | 53 | −0.8% | −2.9% |
| Selling | 18 | +5.3% | +4.7% |
Average ATEC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the ATEC price, zone by zone.Track ATEC in Gekko
Is Alphatec stock overvalued? Gekko Fair Value
Alphatec trades 13.5% below Gekko Fair Value of $13.00, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Alphatec shares are worth, recalculated every trading day.
$13.00
Gekko Fair Value, Oct 10, 2026
13.5% Undervalued
At the end of Aug 2026 the price was 30.2% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ATEC in Gekko
Alphatec insider and Congress trading
Insiders filed 1 open-market purchase in Alphatec worth $1.01M, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ATEC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ATEC, plotted on the chart in Gekko.Open ATEC in Gekko
Buybacks
Alphatec has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2025
- $3.00M
- As a share of market cap
- 0.17%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold ATEC.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Alphatec earnings: next date and track record
Alphatec reports on Oct 29, 2026, after the close (17 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected after the close, 17 days away
- EPS estimate
- $0.10
- Revenue estimate
- $225.5M
4 of 8reports beat the EPS estimate
±19.6%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- ATEC reported a strong Q2 2026: revenue of $214M (up 15% YoY), surgical revenue of $196M (up 17%), case volume +20%, and net new surgeon adds +24%. Adjusted EBITDA was $36M (17% margin), with positive free cash flow and improving gross margins driven by inventory efficiency, design/cost improvements, and favorable mix. EOS revenue was $17M and management emphasized EOS and EOS Insight as a strategic catalyst (Early EOS Insight users show ~32% revenue uplift). Management remains confident in the business model—procedural product integration, surgeon adoption, and a scalable sales organization—and reiterated conviction in long-term growth (including a path toward ~$1B revenue in 2027).
- Guidance
- Management reaffirmed full-year guidance (no quantitative change disclosed on this call). Specific forward-looking pieces discussed: surgical volumes expected to moderate from ~20% in H1 to high-teens in H2; revenue per procedure expected to be down low-single-digits year-over-year (driven by mix and biologics attach assumptions); free cash flow target of $20M+ for the full year; second-half gross margin profile expected to improve (management referenced a mid-70s-ish gross margin target implied near ~71% in the second half vs prior guidance). Management also articulated ambition to scale toward $1B+ in revenue in 2027.
- Risks flagged
- Biologics attachment rates remain below prior-year levels and were a primary driver of softer revenue-per-procedure; revenue/mix headwinds from international and cervical adoption; installation/space and capital constraints for EOS units (installation dynamics and site selection can slow placements); competition and execution risk for Theradaptive/BMP-related offerings; execution risk in scaling EOS Insight and data-sharing integration; inventory and set-investment timing risks tied to seasonal deployment.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$0.16 est −$0.12 | $213.5M est $211.3M | −5.7% |
| May 5, 2026 | −$0.22 est $0.00 | $192.1M est $197.5M | −32.3% |
| Feb 24, 2026 | $0.06 est $0.04 | $212.9M est $211.5M | +6.7% |
| Oct 30, 2025 | $0.03 est −$0.03 | $196.5M est $209.2M | +15.2% |
| Jul 31, 2025 | $0.02 est −$0.04 | $185.5M est $182.6M | +28.3% |
| May 1, 2025 | −$0.09 est −$0.12 | $169.2M est $178.9M | +9.3% |
| Feb 26, 2025 | −$0.06 est −$0.04 | $176.8M est $172.7M | +14.8% |
| Oct 30, 2024 | −$0.28 est −$0.25 | $150.7M est $170.3M | +44.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Alphatec stock forecast and analyst price targets
Analysts’ average 12-month price target for Alphatec is $15.79, +40.4% from the last close, from 11 firms rating the stock in the last 90 days.
$15.79consensus 12-month target, +40.4% from the last close
Now $11.25Avg $15.79
Low $10.54High $24
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 7 | Stifel Nicolaus | $10.54 | −6.3% |
| Aug 5 | BMO Capital | $12 | +6.7% |
| Aug 5 | BMO Capital | $12 | +6.7% |
| Aug 5 | UBS | $16 | +42.2% |
| Aug 5 | Lake Street | $15 | +33.3% |
−1.6%average 20-day move after past Neutral readings
+23.4%average move over the next 20 trading days in the last 5 years
±4.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Alphatec seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Alphatec averaged +23.4% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.1% | 2 of 5 |
| Next 10 trading days | +6.7% | 3 of 5 |
| Next 15 trading days | +7.7% | 4 of 5 |
| Next 20 trading days | +23.4% | 4 of 5 |
| Next 30 trading days | +26.5% | 3 of 5 |
For scale, ATEC’s typical 20-trading-day move in either direction is about 10.1%.
Alphatec market cap and key statistics
Alphatec’s market cap is $1.73B and revenue of $815.1M over the last twelve months.
Valuation
- Market cap
- $1.73B
- Forward P/E
- 18.6
- EPS, TTM
- −$0.72
- Gekko Fair Value
- $13.00
Trading
- Volume
- 2.95M
- Avg volume, 20 days
- 2.14M
- 52-week high
- $23.29
- 52-week low
- $6.82
- Shares outstanding
- 154.5M
Financials
- Revenue, TTM
- $815.1M
- Profit margin
- -13.5%
- Return on equity
- -373.4%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.78
- Typical daily move
- ±4.1%
- Typical 20-day move
- ±10.1%
Alphatec stock news this week
Coverage of Alphatec this week reads positive: 2 positive, 2 neutral and 0 negative headlines.
- Analysts Are Bullish on These Healthcare Stocks: Zura Bio (ZURA), Alphatec Holdings (ATEC)The Globe and Mail, Oct 9
- Trading the Move, Not the Narrative: (ATEC) EditionStock Traders Daily, Oct 6
- Form 4 Alphatec Holdings Inc For: 5 October By Investing.comInvesting.com Canada, Oct 6
- Form 4 Alphatec Holdings Inc For: 5 OctoberInvesting.com India, Oct 6
Alphatec peers
Alphatec’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
Alphatec stock FAQ
What is Alphatec’s market cap?
Alphatec’s market cap is $1.73B at the Oct 12, 2026 close of $11.25, with 154.5M shares outstanding.
What is the Alphatec stock forecast?
The consensus analyst 12-month price target for Alphatec is $15.79, +40.4% from the last close. Of the 11 firms that rated the stock in the last 90 days, 11 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Alphatec stock overvalued or undervalued?
On Gekko’s estimate Alphatec is undervalued: the Oct 12, 2026 close of $11.25 is 13.5% below Gekko Fair Value of $13.00. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Alphatec report earnings next?
Alphatec is expected to report on Oct 29, 2026, after the market closes (17 days away). Analysts expect earnings of $0.10 per share on revenue of $225.5M. Alphatec beat the earnings estimate in 4 of its last 8 reports, moving 19.6% on average across the report.
What is Alphatec’s 52-week high and low?
Alphatec’s 52-week high is $23.29 and its 52-week low is $6.82; it closed at $11.25 on Oct 12, 2026, −18.2% over the past year.
Is Alphatec stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (fair value, smart money and seasonality), 2 as mixed (trend and gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Alphatec the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.